지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
This article aimed to introduce 'risk sharing' schemes for pharmaceuticals between drug manufacturers and healthcare payer. Published literature review was undertaken to summarize risk sharing concepts and collect information on existing scheme examples in other countries focusing on new anticancer drugs. Risk sharing schemes could be categorized into health outcomes-based and non-outcomes (financial) based ones. Outcome-based schemes could be broken down into performance-linked reimbursement and conditional coverage. Performance-linked reimbursement can be further broken into outcomes guarantee and pattern or process of care and conditional coverage included coverage with evidence development and conditional treatment continuation schemes. Non-outcome based schemes included market share and price volume at population level, and utilization caps and manufacturer funded treatment initiation at patient level. We reviewed the fifteen examples for anticancer drugs that risk sharing agreements in response to the inherent uncertainties and increased costs of eleven anticancer drugs. Of them, eight cases were coverage with evidence development schemes. The anticancer drugs except bevacizumab and cetuximab were all listed on the national health insurance formulary in Korea, with reimbursement criteria defined on the basis of approved indications and administrations. Risk sharing approach may be a useful tool to ensure values for drug expenditure, but there are a number of concerns such as high administration costs, lack of transparency and conflicts of interest, especially for performance-based health outcomes reimbursement schemes.
목차
등록된 정보가 없습니다.
참고문헌 (18)
참고문헌 신청
/ / 약업신문 보도자료
Adamski J / 2010 / Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers / BMC Health Serv Res 10 : 153 ~
CMS / / Coverage with Evidence Development
Carlson JJ / 2010 / examination of performance-based reimbursement schemes between healthcare payers and manufacturers / Health Policy 96 : 17990 ~
Cohen JP / 2011 / Risk-Sharing: Why, What, and Where / The 23rd AMCP Annual Meeting
Adamski J / 2010 / Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers / BMC Health Serv Res 10 : 153 ~
CMS / / Coverage with Evidence Development
Carlson JJ / 2010 / examination of performance-based reimbursement schemes between healthcare payers and manufacturers / Health Policy 96 : 17990 ~
Cohen JP / 2011 / Risk-Sharing: Why, What, and Where / The 23rd AMCP Annual Meeting
이 논문의 저자 정보
최근 본 자료
댓글(0)
0